Actively Recruiting
Effect of Acute Normovolemic Hemodilution on Blood Transfusions During Bone Tumor Surgery A Randomized Controlled Trial in Adults Aged 18 to 75
Led by Second Affiliated Hospital, Zhejiang University, School of Medicine · Updated on 2026-06-25
150
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Bone tumor surgery carries a high risk of significant blood loss and the need for transfusion, which can lead to complications and affect long-term outcomes for patients. Researchers are studying whether acute normovolemic hemodilution ANH, a blood management procedure, can reduce the volume of allogeneic red blood cell transfusions during bone cancer surgery. The HEAL trial is a randomized, controlled study designed to evaluate this effect in patients undergoing bone tumor surgery. In this trial, participants are assigned to either receive ANH or standard care during surgery. ANH involves drawing blood after tracheal intubation and replacing it with a fluid solution to maintain blood volume, followed by goal-directed fluid therapy until surgery ends. The control group receives only goal-directed fluid therapy without ANH. The study aims to compare the amount of blood transfused during surgery between these two groups. Participants will be monitored from the start to the end of surgery for transfusion volume and blood loss. Additional assessments include coagulation tests, hemodynamic measurements, transfusion rates, infection rates, embolic events, and hospital stay length up to one year. The research team will collect data perioperatively and follow up until discharge or seven days post-operation, with longer observation for hospital stay outcomes.
CONDITIONS
Brief Title
The Effect of Acute Normovolemic Hemodilution in Bone Tumor Surgery
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here